July 18, 2019 09:20 AM EDT

As Acthar troubles persist, Mallinckrodt invests in RNAi and Silence Therapeutics

Natalie Grover

Reporter

A day after it was forced to ax an amyotrophic lateral sclerosis study testing its controversial Acthar gel, Mallinckrodt is investing in RNA technology to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Acthar troubles persist, Mallinckrodt invests in RNAi and Silence Therapeutics

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

As Ac­thar trou­bles per­sist, Mallinck­rodt in­vests in RNAi and Si­lence Ther­a­peu­tics

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

As Acthar troubles persist, Mallinckrodt invests in RNAi and Silence Therapeutics